Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

82.93 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

November 03, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025

October 28, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup ↗

October 18, 2025

Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.

Via Chartmill

8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know ↗

October 16, 2025

Via Benzinga

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Preview: Mirum Pharmaceuticals's Earnings ↗

May 06, 2025

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup ↗

September 27, 2025

Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.

Via Chartmill

This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

September 24, 2025

Via Benzinga

Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews ↗

September 12, 2025

Via Benzinga

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study

September 08, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential ↗

September 05, 2025

Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch.

Via Chartmill

MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template ↗

August 30, 2025

MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors.

Via Chartmill

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

August 27, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

August 08, 2025

Via Benzinga

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance ↗

August 06, 2025

Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

August 06, 2025

Via Benzinga

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 06, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum ↗

August 06, 2025

Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.

Via Chartmill

Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025

July 30, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 10, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Appoints Doug Sheehy, JD, as Chief Legal Officer

May 19, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

May 14, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 09, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Beyond The Numbers: 4 Analysts Discuss Mirum Pharmaceuticals Stock ↗

May 09, 2025

Via Benzinga

Volixibat Data from Mirum’s VANTAGE PBC Study Showcased at EASL

May 09, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 07, 2025

From Mirum Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.